These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36093444)

  • 1. Case series of nebulizing r-tPA for COVID-19 induced acute respiratory distress syndrome.
    Amini S; Labbani-Motlagh Z; Aliannejad R; Pourabbas SM; Vasei M
    Clin Case Rep; 2022 Sep; 10(9):e6283. PubMed ID: 36093444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome.
    Rehberg S; Yamamoto Y; Sousse LE; Jonkam C; Cox RA; Prough DS; Enkhbaatar P
    J Trauma Acute Care Surg; 2014 Jan; 76(1):126-33. PubMed ID: 24368367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.
    Idell S; James KK; Levin EG; Schwartz BS; Manchanda N; Maunder RJ; Martin TR; McLarty J; Fair DS
    J Clin Invest; 1989 Aug; 84(2):695-705. PubMed ID: 2788176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients.
    Zuo Y; Warnock M; Harbaugh A; Yalavarthi S; Gockman K; Zuo M; Madison JA; Knight JS; Kanthi Y; Lawrence DA
    Sci Rep; 2021 Jan; 11(1):1580. PubMed ID: 33452298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19.
    Wygrecka M; Birnhuber A; Seeliger B; Michalick L; Pak O; Schultz AS; Schramm F; Zacharias M; Gorkiewicz G; David S; Welte T; Schmidt JJ; Weissmann N; Schermuly RT; Barreto G; Schaefer L; Markart P; Brack MC; Hippenstiel S; Kurth F; Sander LE; Witzenrath M; Kuebler WM; Kwapiszewska G; Preissner KT
    Blood Adv; 2022 Feb; 6(3):1074-1087. PubMed ID: 34861681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome.
    Cederqvist K; Sirén V; Petäjä J; Vaheri A; Haglund C; Andersson S
    Pediatrics; 2006 Apr; 117(4):1226-34. PubMed ID: 16585319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial.
    Barrett CD; Moore HB; Moore EE; Wang J; Hajizadeh N; Biffl WL; Lottenberg L; Patel PR; Truitt MS; McIntyre RC; Bull TM; Ammons LA; Ghasabyan A; Chandler J; Douglas IS; Schmidt EP; Moore PK; Wright FL; Ramdeo R; Borrego R; Rueda M; Dhupa A; McCaul DS; Dandan T; Sarkar PK; Khan B; Sreevidya C; McDaniel C; Grossman Verner HM; Pearcy C; Anez-Bustillos L; Baedorf-Kassis EN; Jhunjhunwala R; Shaefi S; Capers K; Banner-Goodspeed V; Talmor DS; Sauaia A; Yaffe MB
    Chest; 2022 Mar; 161(3):710-727. PubMed ID: 34592318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review.
    Schultz MJ; Haitsma JJ; Zhang H; Slutsky AS
    Crit Care Med; 2006 Mar; 34(3):871-7. PubMed ID: 16521285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired fibrinolysis in critically ill COVID-19 patients.
    Bachler M; Bösch J; Stürzel DP; Hell T; Giebl A; Ströhle M; Klein SJ; Schäfer V; Lehner GF; Joannidis M; Thomé C; Fries D
    Br J Anaesth; 2021 Mar; 126(3):590-598. PubMed ID: 33422287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Polytrauma and Acute Respiratory Distress Syndrome on Markers of Fibrinolysis: A Prospective Pilot Study.
    Negrin LL; Dedeyan M; Plesser S; Hajdu S
    Front Med (Lausanne); 2020; 7():194. PubMed ID: 32582720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome.
    Günther A; Mosavi P; Heinemann S; Ruppert C; Muth H; Markart P; Grimminger F; Walmrath D; Temmesfeld-Wollbrück B; Seeger W
    Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):454-62. PubMed ID: 10673185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown.
    Gurewich V
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):749-753. PubMed ID: 31897763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of surgical trauma on rat peritoneal fibrinolytic activity and its role in adhesion formation.
    Hellebrekers BW; Trimbos-Kemper GC; Bakkum EA; Trimbos JB; Declerck PJ; Kooistra T; Emeis JJ
    Thromb Haemost; 2000 Nov; 84(5):876-81. PubMed ID: 11127871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome.
    Groeneveld AB; Kindt I; Raijmakers PG; Hack CE; Thijs LG
    Thromb Haemost; 1997 Dec; 78(6):1444-9. PubMed ID: 9423792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid molecules: insights into plasminogen activator function.
    Runge MS; Bode C; Haber E; Quertermous T
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.